Genome-wide association reveals a locus in neuregulin 3 associated with gabapentin efficacy in women with chronic pelvic pain.

Chronic pelvic pain (CPP) in women with no obvious pelvic pathology has few evidence-based treatment options. Our recent multicenter randomized controlled trial (GaPP2) in women with CPP and no obvious pelvic pathology showed that gabapentin did not relieve pain overall and was associated with more side effects than placebo. We conducted an exploratory genome-wide association study using eligible GaPP2 participants aiming to identify genetic variants associated with gabapentin response. One genome-wide significant association with gabapentin analgesic response was identified, rs4442490, an intron variant located in Neuregulin 3 (

Informations de copyright

Crown Copyright © 2024 Published by Elsevier Inc.

Déclaration de conflit d'intérêts

SCM, NR, KV, KTZ, AWH, and LHRW are listed as co-inventors on a patent application (UK Patent App No. 2217921.2, International Patent App No. PCT/GB2023/053076) relating to the use of the NRG3 loci presented herein as a predictive test to determine the efficacy of gabapentin for chronic pelvic pain treatment. AWH’s institution has received honoraria for consultancy from Roche Diagnostics, Gesynta, and Joii, and he has received lecture fees from Theramex. AWH and LHRW’s institution has received grant funding from Roche Diagnostics. KV reports grant funding to the Institution from Bayer AG and honoraria for consultancy paid to the Institution from Bayer AG, Abbvie, Reckitts, and Gedeon Richter. KTZ reports grant funding to the Institution from Bayer AG, Roche Diagnostics, MDNA Life Sciences Ltd, and Exeltis Ltd, and royalty payments from scientific collaboration with Bayer AG. The other authors declare no competing interests.